Official Title
Clinical Characteristic and MEFV Gene Mutations in Patient With Juvenile Onset- Systemic Lupus Erythematosus
Brief Title
Clinical Characteristic and MEFV Gene Mutations in Patient With Juvenile Onest Systemic Lupus Erythematosus
Protocol ID
NCT04645225
Lead Sponsor
Assiut University
Brief Summary
Aim and objectives of this study
- To summarize the main clinical characteristics of patients with jSLE admitted and
followed up in Assiut University children's Hospital.
- To compare the MEFV gene mutations in patients with jSLE versus a control group of
healthy children in upper-Egypt a country with a considerably high carrier rate for
the MEFV gene variants.
- To assess the prevalence and clinical significance of jSLE patients carrying MEFV
variants and assess the impact of MEFV gene mutation on disease severity as assessed
by systemic lupus erythematous disease activity index (SLEDAI).
- To assess if there is a specific MEFV gene mutations that are more associated with
jSLE and/or certain disease manifestations, such as serositis
Detailed Description
Systemic lupus erythematosus (SLE) is a chronic autoimmune inflammatory disease
characterized by the presence of multiple auto antibodies and is associated with a
multisystemic illness. The clinical presentation of SLE ranges from mild to severe and
the course of the disease is unpredictable, with periods of remission and flares. (1)
Juvenile-onset systemic lupus erythematosus (jSLE) patients present more frequently in
teenage years and accounts for 15%-20% of lupus population, and they typically have
severe disease course than adult patients. A considerable number of jSLE patients have
significant renal or central nervous system(CNS) involvement at the time of diagnosis.(1)
It is slightly more common in girls, with a sex ratio about 4:3 before puberty; however
after puberty, the sex difference increases to about 4:1.(2) The disease is more common
in Native Americans,African Americans, and Asians. (3) Prevalence rate of jSLE have
varied from 4-250 per 100,000 population.(4,5) JSLE is not rare in Egypt and Africa,
representing an important subset that is commonly overlooked and requires special
attention. (6,7) SLE ranges from an insidious, slowly progressive, chronic disease with
exacerbations and remissions,to an acute and rapidly fatal disease. Constitutiona
lfeatures such as fever, fatigue, anorexia, myalgia,weight loss are common both at onset
and during exacerbations of the disease. (8,9) Familial Mediterranean fever (FMF), an
autosomal recessively inherited autoinflammatory disorder, is characterized by recurrent,
self-limited inflammatory attacks involving mainly serosal membranes. The disease has
been associated with variations in the MEFV gene, which encodes the pyrin protein, in the
great majority of patients.(10) FMF is the most common autoinflammatory disorder, and the
rate of heterozygous carrier for MEFV gene variations is quite high in Eastern
Mediterranean countries, including Turkey, Israel, and Armenia.(11,12) A higher acute
phase response has been reported in asymptomatic heterozygous carriers, and
heterozygosity for MEFV variations has been suggested to affect the course of other
autoinflammatory disorders.(13,14) A connection between FMF and collagen diseases were
suggested previously by multiple studies as that MEFV mutations M694V and M680I were
observed to be associated with Behcet's Disease (BD), (15)Also the MEFV variants in exon
10 were suggested to affect the clinical presentation of Henoch-Schönleinpurpurain
populations where FMF is common. (16) The mutation p.M694V/I in MEFV gene might be a risk
factor for systemic onset juvenile idiopathic arthritis sJIA, (17)and M694V is accepted
to be associated with more severe inflammation as compared to other mutations in patients
with Polyarteritis nodosa.
Study Period
-
Enrollment Count
60 participants
Eligibility Criteria
Inclusion Criteria:
1. Age at enrollment ≤18 years old but they should be diagnosed as jSLE before the age
of 16 years old.
2. Both sexes
3. The Patients should be diagnosed as jSLE according to 2019 European league against
rheumatism (EULAR)/ American college of rheumatology (ACR) SLE classification
criteria, (20) or previous ACR 1997 SLE classification criteria.
4. No suggestive symptoms of FMF as stated by Tel Hashomer criteria
Exclusion Criteria:
- 1- Patients diagnosed as FMF or receiving colchicine for possibility of FMF. 2-
Patients with other autoimmune disease. 3- Patients not fulfilling the criteria for
diagnosis of SLE
Filters
SLE (Systemic Lupus)
UNKNOWN
CHILD
ADULT